Gilead’s Truvada SPC revoked by English High Court
The English High Court has ruled that Gilead’s SPC for an antiretroviral product does not comply with Article 3(a)
Gilead’s supplementary protection (SPC) certificate for antiretroviral product Truvada has been revoked by the English High Court today.
Handing down his judgment in Teva v Gilead, Mr Justice Arnold held that Gilead’s SPC did not satisfy Article 3A of...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.